Overview

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Status:
Unknown status
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Antibodies, Monoclonal
Daratumumab